{"id":"NCT00445939","sponsor":"Abbott","briefTitle":"A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease","officialTitle":"A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-02","primaryCompletion":"2007-12","completion":null,"firstPosted":"2007-03-09","resultsPosted":"2009-03-23","lastUpdate":"2011-06-27"},"enrollment":90,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"placebo","otherNames":[]}],"arms":[{"label":"Adalimumab 160 mg/80 mg","type":"EXPERIMENTAL"},{"label":"Adalimumab 80 mg/40 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.","primaryOutcome":{"measure":"The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4","timeFrame":"4 Weeks","effectByArm":[{"arm":"Adalimumab 160 mg/80 mg","deltaMin":11,"sd":null},{"arm":"Adalimumab 80 mg/40 mg","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":18,"countries":["Japan"]},"refs":{"pmids":["22325170"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Injection site reaction","Nasopharyngitis","Upper respiratory tract infection","Nausea"]}}